Randomized double-blind study of efficacy and safety of topical 3% minoxidil solution combined with 0.25% finasteride solution versus 3% minoxidil solution in treatment of male androgenetic alopecia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20160910002

Enrollment

Registered

2016-09-10

Start date

2015-06-23

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Androgenetic alopecia Androgenetic alopecia Male pattern alopecia Male pattern baldness

Interventions

Topical 3% minoxidil solution combined with 0.25% finasteride solution,Topical 3% minoxidil solution

Experimental Drug,Active Comparator Drug

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Healthy male subject 2.Diagnosis of androgenic alopecia with class III and V Norwood-Hamilton classification 3.Agree to participate and signed informed consent form

Exclusion criteria

Exclusion criteria: 1.History of hair transplant 2.Applying topical hair growth products within 2 weeks 3.Receiving light and laser treatment of the scalp within 3 months 4.Taking oral finasteride within 12 months 5.Taking dutasteride within 18 months 6.History of systemic illness 7.History of scalp diseases eg. seborrheic dermatitis, scalp infection.

Design outcomes

Primary

Measure	Time frame
Efficacy of topical 3% minoxidil solution combined with 0.25% finasteride solution 6 months Hair count and hair diameter	—

Secondary

Measure	Time frame
Safety of topical 3% minoxidil solution combined with 0.25% finasteride solution 6 months Erythema, Scaliness, Inflammation and Systemic side effects	—

Countries

Thailand

Contacts

Public ContactPoonkiat Suchonwanit

Ramathibodi Hospital, Mahidol University

poonkiat@hotmail.com0817348580

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

Randomized double&#45;blind study of efficacy and safety of topical 3% minoxidil solution combined with 0.25% finasteride solution versus 3% minoxidil solution in treatment of male androgenetic alopecia